Ajantha Pharma gets USFDA approval for Zolmitripton Tablets
DSIJ Intelligence / 24 May 2016
Ajantha Pharma on Tuesday announced the receipt of final approval for Zolmitripton Tablets by US Food & Drug Administration.
Ajanta Pharma on Tuesday announced the receipt of final approval for Zolmitripton Tablets by US Food & Drug Administration. Zolmitripton is used in the acute treatment of migraine and is a bio equivalent generic version of Zomig®
The Zolmitripton tablet is a part of a growing portfolio of products that Ajanta has developed specifically for US markets. The company has got 9 abbreviated new drug applications (ANDAs) final approvals so far and 2 tentative approvals with additional 15 ANDAs being under review with the FDA.
Ajanta Pharma closed down by 1.56 percent on Tuesday at Rs.1464 even as broader markets were up by 0.30 percent at 25,305 levels. BSE healthcare was down by 0.88 percent. The stock has delivered 3.54 percent over a 1 year period and over a 3 months period the stock has delivered 13 percent returns. The stock is trading above its 200 day Simple Daily Moving Average (SDMA) indicating bullishness in the scrip. The 52 w High for the stock is 1720 and the 52 w Low for the stock is at 1103.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.